(2023)
Microbiome and immuno-metabolic dysregulation in patients with major depressive disorder with atypical clinical presentation.
Neuropharmacology 235,
109568.
(Review)
Prof. Dr. Gianni Panagiotou
Microbiome Dynamics · Head +49 3641 532-1759 gianni.panagiotou@leibniz-hki.deCurriculum vitae
Main Research Areas
- Medical & Environmental Metagenomics: human, mice, marine, plants;
- Systems Biology: -omics integration, chemical-protein & protein-protein interaction networks;
- Synthetic Biology: genome-scale metabolic modelling, design of probiotics, discovery of postbiotics
Publications
(2023)
Distinct transcriptional responses to fludioxonil in Aspergillus fumigatus and its ΔtcsC and Δskn7 mutants reveal a crucial role for Skn7 in the cell wall reorganizations triggered by this antifungal.
BMC Genomics 24(1),
684.
(2023)
Candida expansion in the gut of lung cancer patients associates with an ecological signature that supports growth under dysbiotic conditions.
Nat Commun 14(1),
2673.
(2022)
From environmental adaptation to host survival: Attributes that mediate pathogenicity of Candida auris.
Virulence 13(1),
191-214.
(2022)
Lactobacillus rhamnosus colonisation antagonizes Candida albicans by forcing metabolic adaptations that compromise pathogenicity.
Nat Commun 13(1),
3192.
(2022)
Candida albicans SR-like protein kinases regulate different cellular processes: Sky1 is involved in control of ion homeostasis, while Sky2 is important for dipeptide utilization.
Front Cell Infect Microbiol 12,
850531.
(2022)
Recent advances in diabetes and microbiota.
Sci Bull 67(17),
1720-1723.
(Review)
(2022)
Potential of microbiome-based solutions for agrifood systems.
Nature Food 3(8),
557-560.
(Review)
(2022)
Risk assessment with gut microbiome and metabolite markers in NAFLD development.
Sci Transl Med 14(648),
eabk0855.
(2022)
Inhibitors of ApiAP2 protein DNA binding exhibit multistage activity against Plasmodium parasites.
PLOS Pathog 18(10),
e1010887.
